Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Karonudib is a promising anticancer therapy in hepatocellular carcinoma.

Hua X, Sanjiv K, Gad H, Pham T, Gokturk C, Rasti A, Zhao Z, He K, Feng M, Zang Y, Zhang J, Xia Q, Helleday T, Warpman Berglund U.

Ther Adv Med Oncol. 2019 Aug 23;11:1758835919866960. doi: 10.1177/1758835919866960. eCollection 2019.

2.

Computational and Experimental Druggability Assessment of Human DNA Glycosylases.

Michel M, Visnes T, Homan EJ, Seashore-Ludlow B, Hedenström M, Wiita E, Vallin K, Paulin CBJ, Zhang J, Wallner O, Scobie M, Schmidt A, Jenmalm-Jensen A, Warpman Berglund U, Helleday T.

ACS Omega. 2019 Jul 5;4(7):11642-11656. doi: 10.1021/acsomega.9b00162. eCollection 2019 Jul 31.

3.

The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity.

Espinoza JA, Zisi A, Kanellis DC, Carreras-Puigvert J, Henriksson M, Hühn D, Watanabe K, Helleday T, Lindström MS, Bartek J.

Cell Death Differ. 2019 Jul 8. doi: 10.1038/s41418-019-0387-5. [Epub ahead of print]

PMID:
31285544
4.

Structural basis of inhibition of the human serine hydroxymethyltransferase SHMT2 by antifolate drugs.

Scaletti E, Jemth AS, Helleday T, Stenmark P.

FEBS Lett. 2019 Jul;593(14):1863-1873. doi: 10.1002/1873-3468.13455. Epub 2019 Jun 10.

PMID:
31127856
5.

Restriction of AID activity and somatic hypermutation by PARP-1.

Tepper S, Mortusewicz O, Członka E, Bello A, Schmidt A, Jeschke J, Fischbach A, Pfeil I, Petersen-Mahrt SK, Mangerich A, Helleday T, Leonhardt H, Jungnickel B.

Nucleic Acids Res. 2019 Aug 22;47(14):7418-7429. doi: 10.1093/nar/gkz466.

6.

The DNA Damaging Revolution: PARP Inhibitors and Beyond.

Yap TA, Plummer R, Azad NS, Helleday T.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:185-195. doi: 10.1200/EDBK_238473. Epub 2019 May 17.

PMID:
31099635
7.

Making immunotherapy 'cold' tumours 'hot' by chemotherapy-induced mutations-a misconception.

Helleday T.

Ann Oncol. 2019 Mar 1;30(3):360-361. doi: 10.1093/annonc/mdz013. No abstract available.

PMID:
30698643
8.

Crystal Structure and Substrate Specificity of the 8-oxo-dGTP Hydrolase NUDT1 from Arabidopsis thaliana.

Jemth AS, Scaletti E, Carter M, Helleday T, Stenmark P.

Biochemistry. 2019 Feb 19;58(7):887-899. doi: 10.1021/acs.biochem.8b00950. Epub 2019 Jan 16.

PMID:
30614695
9.

Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation.

Visnes T, Cázares-Körner A, Hao W, Wallner O, Masuyer G, Loseva O, Mortusewicz O, Wiita E, Sarno A, Manoilov A, Astorga-Wells J, Jemth AS, Pan L, Sanjiv K, Karsten S, Gokturk C, Grube M, Homan EJ, Hanna BMF, Paulin CBJ, Pham T, Rasti A, Berglund UW, von Nicolai C, Benitez-Buelga C, Koolmeister T, Ivanic D, Iliev P, Scobie M, Krokan HE, Baranczewski P, Artursson P, Altun M, Jensen AJ, Kalderén C, Ba X, Zubarev RA, Stenmark P, Boldogh I, Helleday T.

Science. 2018 Nov 16;362(6416):834-839. doi: 10.1126/science.aar8048.

10.

Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.

Lallo A, Gulati S, Schenk MW, Khandelwal G, Berglund UW, Pateras IS, Chester CPE, Pham TM, Kalderen C, Frese KK, Gorgoulis VG, Miller C, Blackhall F, Helleday T, Dive C.

Br J Pharmacol. 2019 Feb;176(3):436-450. doi: 10.1111/bph.14542. Epub 2018 Dec 13.

PMID:
30427531
11.

The Cockayne syndrome protein B is involved in the repair of 5-AZA-2'-deoxycytidine-induced DNA lesions.

Burgos-Morón E, Calderón-Montaño JM, Pastor N, Höglund A, Ruiz-Castizo Á, Domínguez I, López-Lázaro M, Hajji N, Helleday T, Mateos S, Orta ML.

Oncotarget. 2018 Oct 12;9(80):35069-35084. doi: 10.18632/oncotarget.26189. eCollection 2018 Oct 12.

12.

MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP.

Jemth AS, Gustafsson R, Bräutigam L, Henriksson L, Vallin KSA, Sarno A, Almlöf I, Homan E, Rasti A, Warpman Berglund U, Stenmark P, Helleday T.

Nucleic Acids Res. 2018 Nov 16;46(20):10888-10904. doi: 10.1093/nar/gky896.

13.

Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination.

Gustafsson NMS, Färnegårdh K, Bonagas N, Ninou AH, Groth P, Wiita E, Jönsson M, Hallberg K, Lehto J, Pennisi R, Martinsson J, Norström C, Hollers J, Schultz J, Andersson M, Markova N, Marttila P, Kim B, Norin M, Olin T, Helleday T.

Nat Commun. 2018 Sep 24;9(1):3872. doi: 10.1038/s41467-018-06287-x.

14.

Targeting BER enzymes in cancer therapy.

Visnes T, Grube M, Hanna BMF, Benitez-Buelga C, Cázares-Körner A, Helleday T.

DNA Repair (Amst). 2018 Nov;71:118-126. doi: 10.1016/j.dnarep.2018.08.015. Epub 2018 Aug 25. Review.

15.

Structure-metabolism-relationships in the microsomal clearance of piperazin-1-ylpyridazines.

Llona-Minguez S, Ghassemian A, Baranczewski P, Desroses M, Koolmeister T, Artursson P, Scobie M, Helleday T.

Medchemcomm. 2017 Jul 4;8(7):1553-1560. doi: 10.1039/c7md00230k. eCollection 2017 Jul 1.

16.

Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments.

Liao H, Ji F, Helleday T, Ying S.

EMBO Rep. 2018 Sep;19(9). pii: e46263. doi: 10.15252/embr.201846263. Epub 2018 Aug 13. Review.

17.

STAT3 differential scanning fluorimetry and differential scanning light scattering assays: Addressing a missing link in the characterization of STAT3 inhibitor interactions.

Desroses M, Busker S, Astorga-Wells J, Attarha S, Kolosenko I, Zubarev RA, Helleday T, Grandér D, Page BDG.

J Pharm Biomed Anal. 2018 Oct 25;160:80-88. doi: 10.1016/j.jpba.2018.07.018. Epub 2018 Jul 17.

18.

A synthetic diphosphoinositol phosphate analogue of inositol trisphosphate.

Riley AM, Unterlass J, Konieczny V, Taylor CW, Helleday T, Potter BVL.

Medchemcomm. 2018 Jul 1;9(7):1105-1113. doi: 10.1039/C8MD00149A. Epub 2018 Jun 4.

19.

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma.

Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Bagge RO, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA.

Cell Death Dis. 2018 Jul 24;9(8):810. doi: 10.1038/s41419-018-0865-6.

20.

Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity.

Berglund E, Maaskola J, Schultz N, Friedrich S, Marklund M, Bergenstråhle J, Tarish F, Tanoglidi A, Vickovic S, Larsson L, Salmén F, Ogris C, Wallenborg K, Lagergren J, Ståhl P, Sonnhammer E, Helleday T, Lundeberg J.

Nat Commun. 2018 Jun 20;9(1):2419. doi: 10.1038/s41467-018-04724-5.

21.

Germline variation in the oxidative DNA repair genes NUDT1 and OGG1 is not associated with hereditary colorectal cancer or polyposis.

Mur P, Jemth AS, Bevc L, Amaral N, Navarro M, Valdés-Mas R, Pons T, Aiza G, Urioste M, Valencia A, Lázaro C, Moreno V, Puente XS, Stenmark P, Warpman-Berglund U, Capellá G, Helleday T, Valle L.

Hum Mutat. 2018 Sep;39(9):1214-1225. doi: 10.1002/humu.23564. Epub 2018 Jul 4.

PMID:
29900613
22.

An orthotopic glioblastoma animal model suitable for high-throughput screenings.

Pudelko L, Edwards S, Balan M, Nyqvist D, Al-Saadi J, Dittmer J, Almlöf I, Helleday T, Bräutigam L.

Neuro Oncol. 2018 Oct 9;20(11):1475-1484. doi: 10.1093/neuonc/noy071.

PMID:
29750281
23.

Human NUDT22 Is a UDP-Glucose/Galactose Hydrolase Exhibiting a Unique Structural Fold.

Carter M, Jemth AS, Carreras-Puigvert J, Herr P, Martínez Carranza M, Vallin KSA, Throup A, Helleday T, Stenmark P.

Structure. 2018 Feb 6;26(2):295-303.e6. doi: 10.1016/j.str.2018.01.004.

24.

Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Page BDG, Valerie NCK, Wright RHG, Wallner O, Isaksson R, Carter M, Rudd SG, Loseva O, Jemth AS, Almlöf I, Font-Mateu J, Llona-Minguez S, Baranczewski P, Jeppsson F, Homan E, Almqvist H, Axelsson H, Regmi S, Gustavsson AL, Lundbäck T, Scobie M, Strömberg K, Stenmark P, Beato M, Helleday T.

Nat Commun. 2018 Jan 17;9(1):250. doi: 10.1038/s41467-017-02293-7.

25.

Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer.

Thålin C, Lundström S, Seignez C, Daleskog M, Lundström A, Henriksson P, Helleday T, Phillipson M, Wallén H, Demers M.

PLoS One. 2018 Jan 11;13(1):e0191231. doi: 10.1371/journal.pone.0191231. eCollection 2018.

26.

Crystal Structures and Inhibitor Interactions of Mouse and Dog MTH1 Reveal Species-Specific Differences in Affinity.

Narwal M, Jemth AS, Gustafsson R, Almlöf I, Warpman Berglund U, Helleday T, Stenmark P.

Biochemistry. 2018 Feb 6;57(5):593-603. doi: 10.1021/acs.biochem.7b01163. Epub 2018 Jan 16.

PMID:
29281266
27.

Glioblastoma and glioblastoma stem cells are dependent on functional MTH1.

Pudelko L, Rouhi P, Sanjiv K, Gad H, Kalderén C, Höglund A, Squatrito M, Schuhmacher AJ, Edwards S, Hägerstrand D, Berglund UW, Helleday T, Bräutigam L.

Oncotarget. 2017 Jul 20;8(49):84671-84684. doi: 10.18632/oncotarget.19404. eCollection 2017 Oct 17.

28.

A comprehensive structural, biochemical and biological profiling of the human NUDIX hydrolase family.

Carreras-Puigvert J, Zitnik M, Jemth AS, Carter M, Unterlass JE, Hallström B, Loseva O, Karem Z, Calderón-Montaño JM, Lindskog C, Edqvist PH, Matuszewski DJ, Ait Blal H, Berntsson RPA, Häggblad M, Martens U, Studham M, Lundgren B, Wählby C, Sonnhammer ELL, Lundberg E, Stenmark P, Zupan B, Helleday T.

Nat Commun. 2017 Nov 16;8(1):1541. doi: 10.1038/s41467-017-01642-w.

29.

Distinct mechanistic responses to replication fork stalling induced by either nucleotide or protein deprivation.

Henriksson S, Groth P, Gustafsson N, Helleday T.

Cell Cycle. 2018;17(5):568-579. doi: 10.1080/15384101.2017.1387696. Epub 2018 Apr 2.

30.

Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.

Rudling A, Gustafsson R, Almlöf I, Homan E, Scobie M, Warpman Berglund U, Helleday T, Stenmark P, Carlsson J.

J Med Chem. 2017 Oct 12;60(19):8160-8169. doi: 10.1021/acs.jmedchem.7b01006. Epub 2017 Oct 3.

PMID:
28929756
31.

Chemotherapy-induced toxicity-a secondary effect caused by released DNA?

Helleday T.

Ann Oncol. 2017 Sep 1;28(9):2054-2055. doi: 10.1093/annonc/mdx349. No abstract available.

PMID:
28911088
32.

Novel spirocyclic systems via multicomponent aza-Diels-Alder reaction.

Llona-Minguez S, Throup A, Steiner E, Lightowler M, Van der Haegen S, Homan E, Eriksson L, Stenmark P, Jenmalm-Jensen A, Helleday T.

Org Biomol Chem. 2017 Sep 26;15(37):7758-7764. doi: 10.1039/c7ob02069d.

PMID:
28891572
33.

Correction to Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors.

Llona-Minguez S, Höglund A, Ghassemian A, Desroses M, Calderón-Montaño JM, Burgos Morón E, Valerie NCK, Wiita E, Almlöf I, Koolmeister T, Mateus A, Cazares-Körner C, Sanjiv K, Homan E, Loseva O, Baranczewski P, Darabi M, Mehdizadeh A, Fayezi S, Jemth AS, Warpman Berglund U, Sigmundsson K, Lundbäck T, Jenmalm Jensen A, Artursson P, Scobie M, Helleday T.

J Med Chem. 2017 Sep 14;60(17):7614. doi: 10.1021/acs.jmedchem.7b01137. Epub 2017 Sep 1. No abstract available.

PMID:
28862438
34.

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.

Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O'Neill C, Zecchini VR, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal D, Helleday T.

Nat Commun. 2017 Aug 29;8(1):374. doi: 10.1038/s41467-017-00393-y.

35.

Tetrahydrobenzothiophene carboxamides: Beyond the kinase domain and into the fatty acid realm.

Llona-Minguez S, Fayezi S, Alihemmati A, Juárez-Jiménez J, Piedrafita FJ, Helleday T.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4462-4466. doi: 10.1016/j.bmcl.2017.08.006. Epub 2017 Aug 5.

PMID:
28807439
36.

Zebularine induces replication-dependent double-strand breaks which are preferentially repaired by homologous recombination.

Orta ML, Pastor N, Burgos-Morón E, Domínguez I, Calderón-Montaño JM, Huertas Castaño C, López-Lázaro M, Helleday T, Mateos S.

DNA Repair (Amst). 2017 Sep;57:116-124. doi: 10.1016/j.dnarep.2017.07.002. Epub 2017 Jul 12.

PMID:
28732309
37.

Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 1: Triazoles, triazolopyrimidines, triazinoindoles, quinoline hydrazones and arylpiperazines.

Llona-Minguez S, Häggblad M, Martens U, Throup A, Loseva O, Jemth AS, Lundgren B, Scobie M, Helleday T.

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3897-3904. doi: 10.1016/j.bmcl.2017.06.038. Epub 2017 Jun 16.

PMID:
28687206
38.

Mutations in Cancer Cause Gain of Cysteine, Histidine, and Tryptophan at the Expense of a Net Loss of Arginine on the Proteome Level.

Tsuber V, Kadamov Y, Brautigam L, Berglund UW, Helleday T.

Biomolecules. 2017 Jul 3;7(3). pii: E49. doi: 10.3390/biom7030049.

39.

Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 2: Pyridone- and pyrimidinone-derived systems.

Llona-Minguez S, Häggblad M, Martens U, Johansson L, Sigmundsson K, Lundbäck T, Loseva O, Jemth AS, Lundgren B, Jensen AJ, Scobie M, Helleday T.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3219-3225. doi: 10.1016/j.bmcl.2017.06.039. Epub 2017 Jun 15.

PMID:
28655422
40.

Identification of novel small molecules that inhibit STAT3-dependent transcription and function.

Kolosenko I, Yu Y, Busker S, Dyczynski M, Liu J, Haraldsson M, Palm Apergi C, Helleday T, Tamm KP, Page BDG, Grander D.

PLoS One. 2017 Jun 21;12(6):e0178844. doi: 10.1371/journal.pone.0178844. eCollection 2017.

41.

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlström H, Bill-Axelson A, Birgisson H, Björ O, Edqvist PH, Hansson T, Helleday T, Hellman P, Henriksson K, Hesselager G, Hultdin M, Häggman M, Höglund M, Jonsson H, Larsson C, Lindman H, Ljuslinder I, Mindus S, Nygren P, Pontén F, Riklund K, Rosenquist R, Sandin F, Schwenk JM, Stenling R, Stålberg K, Stålberg P, Sundström C, Thellenberg Karlsson C, Westermark B, Bergh A, Claesson-Welsh L, Palmqvist R, Sjöblom T.

Acta Oncol. 2018 Feb;57(2):187-194. doi: 10.1080/0284186X.2017.1337926. Epub 2017 Jun 20.

PMID:
28631533
42.

ATM/Wip1 activities at chromatin control Plk1 re-activation to determine G2 checkpoint duration.

Jaiswal H, Benada J, Müllers E, Akopyan K, Burdova K, Koolmeister T, Helleday T, Medema RH, Macurek L, Lindqvist A.

EMBO J. 2017 Jul 14;36(14):2161-2176. doi: 10.15252/embj.201696082. Epub 2017 Jun 12.

43.

Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors.

Llona-Minguez S, Höglund A, Ghassemian A, Desroses M, Calderón-Montaño JM, Burgos Morón E, Valerie NCK, Wiita E, Almlöf I, Koolmeister T, Mateus A, Cazares-Körner C, Sanjiv K, Homan E, Loseva O, Baranczewski P, Darabi M, Mehdizadeh A, Fayezi S, Jemth AS, Warpman Berglund U, Sigmundsson K, Lundbäck T, Jenmalm Jensen A, Artursson P, Scobie M, Helleday T.

J Med Chem. 2017 May 25;60(10):4279-4292. doi: 10.1021/acs.jmedchem.7b00182. Epub 2017 May 16. Erratum in: J Med Chem. 2017 Sep 14;60(17):7614.

PMID:
28508636
44.

With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.

Herold N, Rudd SG, Sanjiv K, Kutzner J, Myrberg IH, Paulin CBJ, Olsen TK, Helleday T, Henter JI, Schaller T.

Exp Hematol. 2017 Aug;52:32-39. doi: 10.1016/j.exphem.2017.05.001. Epub 2017 May 11.

45.

Global survey of the immunomodulatory potential of common drugs.

Vladimer GI, Snijder B, Krall N, Bigenzahn JW, Huber KVM, Lardeau CH, Sanjiv K, Ringler A, Berglund UW, Sabler M, de la Fuente OL, Knöbl P, Kubicek S, Helleday T, Jäger U, Superti-Furga G.

Nat Chem Biol. 2017 Jun;13(6):681-690. doi: 10.1038/nchembio.2360. Epub 2017 Apr 24.

46.

SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.

Herold N, Rudd SG, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, Helleday T, Henter JI, Schaller T.

Cell Cycle. 2017 Jun 3;16(11):1029-1038. doi: 10.1080/15384101.2017.1314407. Epub 2017 Apr 24.

47.

dUTPase inhibition augments replication defects of 5-Fluorouracil.

Hagenkort A, Paulin CBJ, Desroses M, Sarno A, Wiita E, Mortusewicz O, Koolmeister T, Loseva O, Jemth AS, Almlöf I, Homan E, Lundbäck T, Gustavsson AL, Scobie M, Helleday T.

Oncotarget. 2017 Apr 4;8(14):23713-23726. doi: 10.18632/oncotarget.15785.

48.

CHD1: a new treatment biomarker for recombination deficiency in castration resistant prostate cancer?

Helleday T.

Ann Oncol. 2017 Jul 1;28(7):1407-1408. doi: 10.1093/annonc/mdx166. No abstract available.

PMID:
28407028
49.

Validation of an enzyme-linked immunosorbent assay for the quantification of citrullinated histone H3 as a marker for neutrophil extracellular traps in human plasma.

Thålin C, Daleskog M, Göransson SP, Schatzberg D, Lasselin J, Laska AC, Kallner A, Helleday T, Wallén H, Demers M.

Immunol Res. 2017 Jun;65(3):706-712. doi: 10.1007/s12026-017-8905-3.

50.

Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.

Llona-Minguez S, Höglund A, Wiita E, Almlöf I, Mateus A, Calderón-Montaño JM, Cazares-Körner C, Homan E, Loseva O, Baranczewski P, Jemth AS, Häggblad M, Martens U, Lundgren B, Artursson P, Lundbäck T, Jenmalm Jensen A, Warpman Berglund U, Scobie M, Helleday T.

J Med Chem. 2017 Mar 9;60(5):2148-2154. doi: 10.1021/acs.jmedchem.6b01786. Epub 2017 Feb 15.

PMID:
28145708

Supplemental Content

Loading ...
Support Center